Clinical Oncology
Volume 20, Issue 8 , Pages 626-630 , October 2008

Management and Survival Trends in Advanced Colorectal Cancer

  • T. Price

      Affiliations

    • The Queen Elizabeth Hospital, Woodville, Australia
    • Lyell McEwin Hospital, Elizabeth Downs, Australia
    • Corresponding Author InformationAuthor for correspondence: T. Price, Department of Oncology, The Queen Elizabeth Hospital, Woodville Road, Woodville, South Australia 5011, Australia. Tel: +61-8-82228429; Fax: +61-8-82227054.
    • ,
  • K. Pittman

      Affiliations

    • The Queen Elizabeth Hospital, Woodville, Australia
    • ,
  • W. Patterson

      Affiliations

    • The Queen Elizabeth Hospital, Woodville, Australia
    • Lyell McEwin Hospital, Elizabeth Downs, Australia
    • ,
  • M. Colbeck

      Affiliations

    • The Queen Elizabeth Hospital, Woodville, Australia
    • ,
  • N. Rieger

      Affiliations

    • The Queen Elizabeth Hospital, Woodville, Australia
    • ,
  • P. Hewett

      Affiliations

    • The Queen Elizabeth Hospital, Woodville, Australia
    • ,
  • D. Rodda

      Affiliations

    • The Queen Elizabeth Hospital, Woodville, Australia
    • ,
  • A. Townsend

      Affiliations

    • The Queen Elizabeth Hospital, Woodville, Australia
    • ,
  • G. Maddern

      Affiliations

    • The Queen Elizabeth Hospital, Woodville, Australia
    • ,
  • C. Luke

      Affiliations

    • Department of Health, SA, Australia
    • ,
  • D. Roder

      Affiliations

    • Cancer Council, SA, Australia

Received 10 January 2008 ,Revised 31 March 2008 ,Accepted 1 April 2008.

References 

  1. Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J. 1993;306(6880):752–755
  2. Meta-analysis Group in Cancer . Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16(1):301–308
  3. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30
  4. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004;22(2):229–237
  5. Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94(7):982–999
  6. Gondos A, Arndt V, Holleczek B, et al. Cancer survival in Germany and the United States at the beginning of the 21st century: an up-to-date comparison by period analysis. Int J Cancer. 2007;121(2):395–400
  7. Luke CG, Koczwara B, Moore JE, et al. Treatment and survival from colorectal cancer: the experience of patients at South Australian teaching hospitals between 1980 and 2002. Clin Oncol. 2005;17:372–381
  8. Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996;14(4):1128–1135
  9. Cunningham D, Pyrhonen S, James RD, et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352(9138):1413–1418
  10. Price TJ, Pittman K, Patterson K, et al. Survival and treatment trends for advanced colorectal cancer treatment in a university hospital, 1992–2001. J Clin Oncol. 2004;22(Suppl):3707a
  11. Koeller JM, Kwan P, McKibbin T, et al. Advanced colorectal cancer treatment and outcome in the community oncology setting. J Clin Oncol. 2006;20(24):16040a
  12. Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil–leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22(7):1209–1214
  13. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343(13):905–914
  14. Hebert-Croteau N, Brisson J, Lemaire J, et al. The benefit of participating to clinical research. Br J Cancer Res Treat. 2005;91(3):279–281
  15. Peppercorn J, Weeks J, Cook EF, et al. Comparison of outcomes in cancer patients within and outside clinical trials: conceptual framework and structured review. Lancet. 2004;363:263–270
  16. Michael M, Goldstein D, Clarke SJ, et al. Prognostic factors predictive of response and survival to a modified FOLFOX regimen: importance of an increased neutrophil count. Clin Colorectal Cancer. 2006;6:297–304

1 Presented in part at the 42nd annual meeting of the American Society of Clinical Oncology, Atlanta, Georgia, USA, 2–6 June 2006.

PII: S0936-6555(08)00244-6

doi: 10.1016/j.clon.2008.04.014

Clinical Oncology
Volume 20, Issue 8 , Pages 626-630 , October 2008

Article Tools

* Image Usage & Resolution